209 related articles for article (PubMed ID: 36809528)
1. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
2. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
3. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
Front Oncol; 2022; 12():980765. PubMed ID: 36033444
[TBL] [Abstract][Full Text] [Related]
4. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
5. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
Betof Warner A; Tarhini A; Kang B; Nakasato A; Ling YL; Shah R; Tang J; Patel J
Melanoma Res; 2023 Feb; 33(1):38-49. PubMed ID: 36545921
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
[TBL] [Abstract][Full Text] [Related]
12. Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E; Hulo P; Guardiolle V; Bodot L; Rabeau A; Porte M; Hiret S; Demontrond P; Curcio H; Boudoussier A; Veillon R; Mayenga M; Dumenil C; Chatellier T; Gourraud PA; Mazieres J; Bennouna J
Cancer Immunol Immunother; 2023 Jun; 72(6):1881-1890. PubMed ID: 36690799
[TBL] [Abstract][Full Text] [Related]
13. Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer.
MacDonald M; Poei D; Leyba A; Diep R; Chennapan K; Leon C; Xia B; Nieva JJ; Hsu R
Cancer Treat Res Commun; 2023; 36():100752. PubMed ID: 37611343
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
[No Abstract] [Full Text] [Related]
15. Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Levy BP; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Parisi M
Curr Oncol; 2019 Jun; 26(3):e300-e308. PubMed ID: 31285672
[TBL] [Abstract][Full Text] [Related]
16. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer.
Bazhenova L; Kish J; Cai B; Caro N; Feinberg B
Cancer Treat Res Commun; 2022; 33():100637. PubMed ID: 36162323
[TBL] [Abstract][Full Text] [Related]
17. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan.
Abu Hejleh T; AlSawalha K; Abdel Hafiz S; Al-Batsh T; Abu Hejleh R; Yaser S; Abu Jazar H; Khader J; Alnsour A; Mohamad I; Abdel Jalil R; Abu-Shanab A; Gharaibeh A; Abu Shattal M; Alibraheem A; Haddad H; Mahmoud N; Obeidat S; Al-Jaghbeer MJ; Furqan M; Cortellini A; Velcheti V; Al-Rabi K
Front Oncol; 2024; 14():1369126. PubMed ID: 38746680
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
19. Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.
Kartolo A; Deluce J; Hopman WM; Liu L; Baetz T; Ernst S; Lenehan JG
Curr Oncol; 2022 Mar; 29(3):1501-1513. PubMed ID: 35323326
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Porte M; Vaudron A; Crequit P; Vaugier L; Chatellier T; Fronteau C; Raimbourg J; Goronflot T; Bennouna J; Pons-Tostivint E
Clin Lung Cancer; 2024 Mar; 25(2):e101-e111.e2. PubMed ID: 38072729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
